<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26547319</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of molecular neuroscience : MN</Title><ISOAbbreviation>J Mol Neurosci</ISOAbbreviation></Journal><ArticleTitle>Spinal and Bulbar Muscular Atrophy Overview.</ArticleTitle><Pagination><StartPage>317</StartPage><EndPage>320</EndPage><MedlinePgn>317-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12031-015-0674-7</ELocationID><Abstract><AbstractText>Spinal and bulbar muscular atrophy is an X-linked neuromuscular disease caused by an expanded repeat in the androgen receptor gene. The mutant protein is toxic to motor neurons and muscle. The toxicity is ligand-dependent and likely involves aberrant interaction of the mutant androgen receptor with other nuclear factors leading to transcriptional dysregulation. Various therapeutic strategies have been effective in transgenic animal models, and the challenge now is to translate these strategies into safe and effective treatment in patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fischbeck</LastName><ForeName>Kenneth H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute for Neurological Disorders and Stroke, National Institutes of Health, 35-2A1000, 35 Convent Dr., Bethesda, MD, 20892-3705, USA. kf@ninds.nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZIA NS003038-10</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Mol Neurosci</MedlineTA><NlmUniqueID>9002991</NlmUniqueID><ISSNLinking>0895-8696</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Androgen receptor</Keyword><Keyword MajorTopicYN="N">Polyglutamine</Keyword><Keyword MajorTopicYN="N">Spinal and bulbar muscular atrophy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26547319</ArticleId><ArticleId IdType="mid">NIHMS822832</ArticleId><ArticleId IdType="pmc">PMC5094812</ArticleId><ArticleId IdType="doi">10.1007/s12031-015-0674-7</ArticleId><ArticleId IdType="pii">10.1007/s12031-015-0674-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Banno H, Katsuno M, Suzuki K, et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol. 2009;65:140&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">19259967</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevalier-Larsen ES, O&#x2019;Brien CJ, Wang H, et al. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci. 2004;24:4778&#x2013;4786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729468</ArticleId><ArticleId IdType="pubmed">15152038</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua JP, Reddy SL, Merry DE, et al. Transcriptional activation of TFEB/ZKSCAN3 target genes underlies enhanced autophagy in spinobulbar muscular atrophy. Hum Mol Genet. 2014;23:1376&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3919011</ArticleId><ArticleId IdType="pubmed">24150846</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes CJ, Miranda HC, Frankowski H, et al. Polyglutamine-expanded androgen receptor interferes with TFEB to elicit autophagy defects in SBMA. Nat Neurosci. 2014a;17:1180&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4180729</ArticleId><ArticleId IdType="pubmed">25108912</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes CJ, Ling SC, Guo LT, et al. Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron. 2014b;82:295&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4096235</ArticleId><ArticleId IdType="pubmed">24742458</ArticleId></ArticleIdList></Reference><Reference><Citation>Doi H, Adachi H, Katsuno M, et al. p62/SQSTM1 differentially removes the toxic mutant androgen receptor via autophagy and inclusion formation in a spinal and bulbar muscular atrophy mouse model. J Neurosci. 2013;33:7710&#x2013;7727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618982</ArticleId><ArticleId IdType="pubmed">23637164</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Rhodes LE, Kokkinis AD, et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 2011;10:140&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056353</ArticleId><ArticleId IdType="pubmed">21216197</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischbeck KH. A role for androgen reduction treatment in Kennedy disease? Muscle Nerve. 2013;47:789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4283484</ArticleId><ArticleId IdType="pubmed">23408598</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunseich C, Zukosky K, Kats IR, et al. Stem cell-derived motor neurons from spinal and bulbar muscular atrophy patients. Neurobiol Dis. 2014a;70:12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172362</ArticleId><ArticleId IdType="pubmed">24925468</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunseich C, Kats IR, Bott LC, et al. Early onset and novel features in a spinal and bulbar muscular atrophy patient with a 68. CAG repeat. Neuromuscul Disord. 2014b;24:978&#x2013;981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252652</ArticleId><ArticleId IdType="pubmed">25047668</ArticleId></ArticleIdList></Reference><Reference><Citation>Iida M, Katsuno M, Nakatsuji H, et al. Pioglitazone suppresses neuronal and muscular degeneration caused by polyglutamine-expanded androgen receptors. Hum Mol Genet. 2015;24:314&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">25168383</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Doyu M, et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med. 2003;9:768&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">12754502</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Banno H, Suzuki K, et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:875&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">20691641</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada A, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352:77&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman AP, Yu Z, Murray S, et al. Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep. 2014;7:774&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4356525</ArticleId><ArticleId IdType="pubmed">24746732</ArticleId></ArticleIdList></Reference><Reference><Citation>Minamiyama M, Katsuno M, Adachi H, et al. Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract. Nat Med. 2012;18:1531&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">23023499</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki Y, Adachi H, Katsuno M, et al. Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nat Med. 2012;18:1136&#x2013;1141.</Citation><ArticleIdList><ArticleId IdType="pubmed">22660636</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzolo I, Burnett BG, Young JE, et al. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum Mol Genet. 2007;16:1593&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pubmed">17470458</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzolo I, Stack C, Kong L, et al. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron. 2009;63:316&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735765</ArticleId><ArticleId IdType="pubmed">19679072</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey UB, Nie Z, Batlevi Y, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature. 2007;447:859&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568747</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi C, Bott LC, Chen KL, et al. Insulin-like growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy. Mol Med. 2012;18:1261&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3521783</ArticleId><ArticleId IdType="pubmed">22952056</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi C, Bott LC, Fischbeck KH. Muscle matters in Kennedy&#x2019;s disease. Neuron. 2014;82:251&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086161</ArticleId><ArticleId IdType="pubmed">24742452</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahashi K, Katsuno M, Hung G, et al. Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet. 2015;24(21):5985&#x2013;5994.</Citation><ArticleIdList><ArticleId IdType="pubmed">26231218</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrader JA, Kats I, Kokkinis A, et al. A randomized controlled trial of functional exercise in spinal and bulbar muscular atrophy. Ann Clin Transl Neurol. 2015;2:739&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4531056</ArticleId><ArticleId IdType="pubmed">26273686</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokui K, Adachi H, Waza M, et al. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum Mol Genet. 2009;18:898&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">19066230</ArticleId></ArticleIdList></Reference><Reference><Citation>Waza M, Adachi H, Katsuno M, et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med. 2005;1:1088&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155577</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Chang YJ, Yu IC, et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med. 2007;13:348&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">17334372</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>